Table 4 Atropine and ephedrine needs and associated side effects among groups
Variables | D Group (n = 55) | C Group (n = 55) | P-value | RR (95% CI) |
|---|---|---|---|---|
Primary outcome | ||||
Patients developing PSA hypotension; n, % | 8 (14.5%) | 18 (32.7%) | #0.025* | 0.44 (0.21–0.94) |
Hemodynamic supports | ||||
Atropine; n,% | 7 (12.7%) | 11 (20.0%) | #0.303 | 0.64 (0.27–1.52) |
Ephedrine; n,% | 8 (14.5%) | 18 (32.7%) | #0.025* | 0.44 (0.21–0.94) |
Atropine and Ephedrine; n,% | 7 (12.7%) | 10 (18.2%) | #0.429 | 0.70 (0.29–1.71) |
Time needed for atropine (minute), (n = 7,11) | 8.6 (3.8) | 7.7 (3.4) | ^0.631 | |
Time needed for ephedrine (minute), (n = 8,18) | 10.6 (5.6) | 9.2 (4.6) | ^0.493 | |
Associated side effects | ||||
Nausea; n,% | 7 (12.7%) | 18 (32.7%) | #0.012* | 0.39 (0.18–0.86) |
Vomiting; n,% | 1 (1.8%) | 8 (14.5%) | §0.032* | 0.13 (0.02–0.97) |
Shivering; n,% | 7 (12.7%) | 25 (45.5%) | # < 0.001* | 0.28 (0.13–0.59) |